中国医药导报
中国医药期刊欢迎您 今天是   2025年4月5日星期六
设为首页 | 加入收藏 
 
        首 页      期刊介绍      下载中心      关于本刊      投稿指南      期刊订阅      在线留言      广告合作      联系我们      返回中国当代医药网
中国医药导报  2023, Vol. 20 Issue (30): 117-120    DOI: 10.20047/j.issn1673-7210.2023.30.24
  妇幼医学 本期目录 | 过刊浏览 | 高级检索 |
龙砂开阖枢针法联合来曲唑对多囊卵巢综合征不孕的治疗效果
温丽娜  王淼▲  周亚红
江苏省无锡市中医医院生殖医学科,江苏无锡 214072
Effect of longsha open and close pivot needle method combined with Letrozole in the treatment of infertility with polycystic ovarian syndrome
WEN Lina WANG Miao▲ ZHOU Yahong
Department of Reproductive Medicine, Wuxi Hospital of Traditional Chinese Medicine, Jiangsu Province, Wuxi 214072, China
全文: PDF (592 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      
摘要 目的 探讨龙砂开阖枢针法联合来曲唑对多囊卵巢综合征(PCOS)不孕的治疗效果。 方法 选取2021年6月至2022年10月江苏省无锡市中医医院收治的84例PCOS不孕患者,按照随机数字表法将其分为对照组(给予来曲唑治疗)和观察组(给予龙砂开阖枢针法联合来曲唑治疗),各42例。比较两组临床疗效;比较两组周期排卵率、妊娠率;比较两组治疗前后卵巢体积、子宫内膜厚度、血清性激素[睾酮(T)、雌二醇(E2)、黄体生成素(LH)、卵泡刺激素(FSH)];观察治疗期间不良反应发生情况。 结果 观察组临床疗效优于对照组(P<0.05)。两组周期排卵率比较,差异无统计学意义(P>0.05);观察组妊娠率高于对照组(P<0.05)。治疗后,两组卵巢体积较治疗前降低,子宫内膜厚度较治疗前升高(P<0.05);观察组卵巢体积小于对照组,子宫内膜厚度高于对照组(P<0.05)。治疗后,两组血清T、LH及FSH水平较治疗前降低,E2水平较治疗前升高(P<0.05);观察组血清T、LH及FSH水平低于对照组,E2水平高于对照组(P<0.05)。两组不良反应总发生率比较,差异无统计学意义(P>0.05)。 结论 龙砂开阖枢针法联合来曲唑治疗PCOS不孕患者可提高临床疗效,提高妊娠率,改善子宫内膜容受性、调节性激素水平,且安全可靠。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
温丽娜  王淼▲  周亚红
关键词 多囊卵巢综合征不孕龙砂开阖枢针法来曲唑排卵子宫内膜容受性性激素    
Abstract:Objective To explore the therapeutic effect of longsha open and close pivot needle method combined with Letrozole on infertility with polycystic ovary syndrome (PCOS). Methods A total of 84 infertility patients with PCOS admitted to Wuxi Hospital of Traditional Chinese Medicine, Jiangsu Province from June 2021 to October 2022 were selected, and they were divided into control group (received Letrozole treatment) and observation group (received longsha open and close pivot needle method combined with Letrozole treatment), with 42 cases in each group. The clinical efficacy of two groups were compared; ovulation rate and pregnancy rate of two groups were compared; ovarian volume, endometrial thickness, serum sex hormones (testosterone [T], estradiol [E2], luteinizing hormone [LH], follicle-stimulating hormone [FSH]) of two groups before and after treatment were compared; and the occurrence of adverse reactions during treatment was observed. Results The clinical efficacy of observation group was better than that of control group (P<0.05). There was no difference in ovulation rate between two groups (P>0.05); the pregnancy rate of observation group was higher than that of control group (P<0.05). After treatment, the ovarian volume of two groups was lower than that before treatment, and the endometrial thickness was higher than that before treatment (P<0.05); the ovarian volume of observation group was lower than that of control group, and the endometrial thickness was higher than that of control group (P<0.05). After treatment, the serum T, LH, and FSH levels in two groups were decreased than those before treatment, while E2 levels were increased than those before treatment (P<0.05); and the serum T, LH and FSH levels in observation group were lower than those of control group, while E2 levels were higher than those of control group (P<0.05). There was no difference in the total incidence of adverse drug reactions between two groups (P>0.05). Conclusion Longsha open and close pivot needle method combined with Letrozole in the treatment of infertility with PCOS can improve clinical efficacy, increase pregnancy rate, improve endometrial receptivity, regulate sex hormone levels, and is safe and reliable.
Key wordsPolycystic ovarian syndrome    Infertility    Longsha open and close pivot needle method    Letrozole    Ovulation    Endometrial receptivity    Sex hormone
    
基金资助:江苏省中医药科技发展计划项目(YB2020043)。
通讯作者: ▲通讯作者   
作者简介: 温丽娜(1983.11-),女,硕士,副主任中医师;研究方向:不孕症。
引用本文:   
温丽娜  王淼▲  周亚红. 龙砂开阖枢针法联合来曲唑对多囊卵巢综合征不孕的治疗效果[J]. 中国医药导报, 2023, 20(30): 117-120.
WEN Lina WANG Miao▲ ZHOU Yahong. Effect of longsha open and close pivot needle method combined with Letrozole in the treatment of infertility with polycystic ovarian syndrome. 中国医药导报, 2023, 20(30): 117-120.
链接本文:  
https://www.yiyaodaobao.com.cn/CN/10.20047/j.issn1673-7210.2023.30.24     或     https://www.yiyaodaobao.com.cn/CN/Y2023/V20/I30/117

 

中华人民共和国互联网药品信息服务资格证书(京)-非经营性-2016-0092
京ICP11001767号-2  京公网安备 11010502046598号  期刊出版许可证 广告经营许可证
信息产业部备案管理系统网址 http://beian.miit.gov.cn/state/outPortal/loginPortal.action
投稿热线:010-59626203
本刊地址:北京市朝阳区东四环中路78号楼(大成国际中心B1座)8B02室 邮编:100124
传真:010-59626204 投稿信箱:ddyy@vip.163.com
版权所有:中文传媒集团北京期刊有限公司
技术支持:北京玛格泰克科技发展有限公司